Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. IGEA Pharma N.V.
  6. News
  7. Summary
    IGPH   NL0012768675


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IGEA Pharma N : to submit the listing prospectus to the SIX following the business combination with Blue Sky Natural Resources

09/08/2021 | 03:12am EDT

Hoofddorp, the Netherlands, 06Septmeber 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the application of the listing prospectus to the SIX Swiss Exchange Ltd ('SIX') for the admission of the New IGEA Pharma Shares to trading. The New Shares to be listed in accordance with the International Reporting Standard of SIX will be exclusively issued to current shareholders of Blue Sky Natural Resources Ltd.

Following the Offer to Blue Sky Natural Resources' shareholders that has reached an acceptance level of 99,38%, the listing prospectus has been prepared in accordance with the Swiss Financial Services Act ('FinSA') and submitted to the SIX Exchange Regulation ('SER').

The approval from the SER is expected to come within 20 days and the trading of the New Shares is expected to commence on or about September 27, 2021 (the 'First Day of Trading') under the symbol IGPH, with International Securities Identification Number ('ISIN') NL0012768675 and Swiss Security Number 41217478

About IGEA

IGEA Pharma N.V. focuses on health-tech products. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl


Giovanna Puppo della Gherardesca, Chairman, puppo@igearesearch.com
Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igearesearch.com


This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.


IGEA Pharma NV published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 September 2021 07:11:00 UTC.

© Publicnow 2021
All news about IGEA PHARMA N.V.
10/04IGEA PHARMA N.V. : Gbc ag to start equity coverage of igea pharma
10/04IGEA PHARMA N : GBC AG to start equity coverage of IGEA Pharma
10/01IGEA PHARMA N : H1 Loss Narrows on Gains From Financial Liabilities, Sale of Assets
09/30IGEA PHARMA N.V. : Igea discloses its half-2021 financials
09/30IGEA Pharma N.V. Reports Earnings Results for First Half 2021
09/30Igea Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2021
09/30IGEA PHARMA N : discloses its half-2021 financials
09/27IGEA PHARMA N.V. : Igea has been granted the listing of the new shares from six exchange r..
09/27IGEA PHARMA N : has been granted the listing of the new shares from SIX Exchange Regulatio..
09/08IGEA PHARMA N : to submit the listing prospectus to the SIX following the business combina..
More news
Financials (USD)
Sales 2020 0,08 M - -
Net income 2020 -1,13 M - -
Net Debt 2020 0,03 M - -
P/E ratio 2020 -11,9x
Yield 2020 -
Capitalization 109 M 109 M -
EV / Sales 2019 14 500x
EV / Sales 2020 194x
Nbr of Employees 2
Free-Float 99,3%
Duration : Period :
IGEA Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Vicenzo Moccia Chairman-Management Board
Sector and Competitors
1st jan.Capi. (M$)
IGEA PHARMA N.V.-44.44%109
10X GENOMICS, INC.14.13%17 920
BIOMÉRIEUX-10.49%14 234
DIASORIN S.P.A.9.14%11 829
NATERA, INC.12.97%10 544